Core Points - The article highlights the debut of three companies: He Yuan Bio (688765.SH), Xi'an Yicai (688783.SH), and Bibet (688759.SH) at the Shanghai Stock Exchange listing ceremony on October 28 [1] - These companies are the first batch of new registered firms in the Sci-Tech Innovation Board's growth tier since the "1+6" reform, enhancing the "hard technology" content of the sector [1] Company Summaries - Xi'an Yicai raised a total of 4.636 billion yuan through its initial public offering [1] - He Yuan Bio raised 2.599 billion yuan in its IPO [1] - Bibet secured 1.6 billion yuan from its initial public offering [1] - The total fundraising amount from these three companies is 8.835 billion yuan [1]

公司主营业务为植物分子医药的研发、生产及商业化。 统计显示，公司本次发行总量为8945.14万股，其中，网上发行量为2150.95万股，发行价格为29.06元/ 股，网上发行最终中签率为0.05431344%。公司首发募资金额为25.99亿元，募资主要投向植物源重组人 血清白蛋白产业化基地建设项目、补充流动资金、新药研发项目等。（数据宝） N禾元-U(688765)今日上市，开盘上涨202.82%，截至收盘涨幅扩大至213.49%，全天成交量3432.29万 股，成交额27.82亿元，换手率83.76%。 证券时报·数据宝统计显示，今日共有4只新股上市，截至收盘，N禾元-U涨213.49%，换手率83.76%；N 奕材-U涨198.72%，换手率73.42%；N泰凯英涨188.53%，换手率92.60%；N必贝特-U涨74.41%，换手率 73.25%。N禾元-U为同日上市的新股中涨幅最大的。 | 代码 | 简称 | 最新价（元） | 收盘涨跌幅（%） | 首日换手率（%） | | --- | --- | --- | --- | --- | | 688765 | N禾元-U | 91.10 | 213.49 ...

Core Points - Wuhan Heyuan Biotechnology Co., Ltd. (stock code: 688765) was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, opening at 88.00 yuan and closing at 91.10 yuan, a rise of 213.49% with a trading volume of 2.782 billion yuan and a turnover rate of 83.76% [1] - The company is an innovative biopharmaceutical enterprise with a leading global plant bioreactor technology platform [1] - The controlling shareholder and actual controller is Yang Daichang, who held 15.03% of the shares before the issuance and now holds 11.27% after the issuance, maintaining control over 21.93% of the voting rights [1] Financial Summary - The initial public offering (IPO) price was set at 29.06 yuan per share, with a total of 89.45 million shares issued, raising approximately 259.95 million yuan before expenses [2] - The net amount raised after deducting issuance costs was approximately 243.04 million yuan [2] - The total investment for the projects funded by the IPO includes 190.87 million yuan for the recombinant human albumin industrialization base, 79.37 million yuan for new drug research and development, and 10 million yuan for working capital, totaling 280.24 million yuan [4] Financial Performance - Over the past three and a half years, the company reported total revenue of 75.59 million yuan and a net loss of 564 million yuan [5] - Revenue for the years 2022 to 2025 (first half) was 13.40 million yuan, 24.26 million yuan, 25.22 million yuan, and 12.71 million yuan respectively, with net losses of 143.58 million yuan, 186.96 million yuan, 151.37 million yuan, and 81.63 million yuan [6][7] - The company has a high R&D expenditure relative to revenue, with R&D expenses accounting for 440.08% of revenue in the first half of 2025 [7]

注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 统计显示，公司本次发行总量为8945.14万股，其中，网上发行量为2150.95万股，发行价格为29.06元/ 股，网上发行最终中签率为0.05431344%。公司首发募资金额为25.99亿元，募资主要投向植物源重组人 血清白蛋白产业化基地建设项目、补充流动资金、新药研发项目等。（数据宝） 今日上市新股表现 | 代码 | 简称 | 最新价（元） | 上午收盘涨跌幅（%） | 半日换手率（%） | | --- | --- | --- | --- | --- | | 688783 | N奕材-U | 26.74 | 210.21 | 56.46 | | 920020 | N泰凯英 | 22.96 | 206.13 | 81.66 | | 688765 | N禾元-U | 88.04 | 202.96 | 70.91 | | 688759 | N必贝特-U | 34.44 | 93.70 | 56.85 | （原标题：N禾元-U上午收盘涨202.96% 半日成交23.21亿元） N禾元-U(688765)今日上市，开盘上涨202.82%，截至上午收盘涨幅 ...

Market Overview - The A-share market experienced a significant rally, with the Shanghai Composite Index breaking the 4000-point mark for the first time since August 19, 2015, marking a historic moment after ten years [1] - As of the midday session, the Shanghai Composite Index rose by 0.21% to 4005.44 points, while the Shenzhen Component Index increased by 0.52% and the ChiNext Index surged by 1.35% [1] Trading Data - The trading volume for the day reached 1.36 trillion yuan, with over 3000 stocks rising [1] - Specific index performances included: - Shanghai Composite Index: 4005.44, up 8.50 points (0.21%), with a trading volume of 588.4 billion yuan [2] - Shenzhen Component Index: 13559.57, up 70.17 points (0.52%), with a trading volume of 761.1 billion yuan [2] - ChiNext Index: 3277.97, up 43.52 points (1.35%), with a trading volume of 360.3 billion yuan [2] Sector Performance - The Fujian sector showed strong performance, with notable stocks such as Pingtan Development (000592) achieving a significant rise [3] - The nuclear power sector was active, with stocks like Dongfang Tantalum Industry (000962) and Antai Technology (000969) showing gains [3] - The commercial aerospace sector continued its upward trend, with Aerospace Intelligent Equipment (300455) reaching a historical high [3] - The diamond cultivation concept saw a pullback, with stocks like Huifeng Diamond declining over 5% [3] New Listings - Four new stocks were listed on the A-share market, marking a record high for the number of new listings in a single day this year [3] - Notably, three unprofitable companies—Bibet, Xi'an Yicai, and Heyuan Biology—saw significant opening gains, with Xi'an Yicai opening up 360% [3][5] - The introduction of these unprofitable hard-tech companies to the Sci-Tech Innovation Board indicates a smoother path for such firms to go public [5]

Core Points - The A-share market experienced a significant rally, with the Shanghai Composite Index surpassing the 4000-point mark for the first time in ten years, closing at 4005.44 points, up 0.21% [1][6] - The trading volume reached 1.36 trillion yuan, with over 3000 stocks rising [1] - Key sectors showing strong performance included Fujian, nuclear power, and commercial aerospace, while coal and precious metals sectors faced declines [3] Market Performance - The Shanghai Composite Index rose by 8.50 points, or 0.21%, with a trading volume of 588.4 billion yuan [2] - The Shenzhen Component Index increased by 70.17 points, or 0.52%, with a trading volume of 761.1 billion yuan [2] - The ChiNext Index saw a rise of 43.52 points, or 1.35%, with a trading volume of 360.3 billion yuan [2] Sector Highlights - The Fujian sector was particularly strong, with stocks like Pingtan Development achieving significant gains [3] - The nuclear power sector was active, with companies like Dongfang Tantalum and Antai Technology showing notable performance [3] - The commercial aerospace sector continued its upward trend, with Aerospace Intelligence Equipment reaching new historical highs [3] New Listings - Four new stocks were listed on the A-share market, marking a record high for the year [4] - Notably, three unprofitable companies—Bibet, Xi'an Yicai, and Heyuan Biology—saw substantial opening gains, with Xi'an Yicai opening up 360% [4][5] - The introduction of these companies signifies a smoother path for unprofitable hard-tech enterprises to enter the market [5]

Core Viewpoint - He Yuan Bio (688765.SH) has successfully listed on the Sci-Tech Innovation Board, marking it as one of the first newly registered companies in the growth sector of the board [1] Company Overview - He Yuan Bio was established in 2006 and specializes in research and product development of plant-derived recombinant protein expression technology [1] - The company is recognized as a national high-tech enterprise [1] Market Performance - On its first trading day, He Yuan Bio opened significantly higher, with an increase of 202.82%, starting at a price of 88 CNY per share [1] - By midday closing, the stock price rose by 202.96%, reaching 88.04 CNY per share, resulting in a total market capitalization of 31.474 billion CNY [1] Shareholders - The company's backers include notable entities such as Shanghai Tongsheng, Betta Pharmaceuticals, Optics Valley Biofund, Yifeng Capital, Xinxin Capital, Wanhua Hongyuan, and Huaxi Bio [1]

Core Viewpoint - The China Securities Regulatory Commission (CSRC) aims to deepen comprehensive reforms in the capital market to enhance its inclusiveness, adaptability, attractiveness, and competitiveness, thereby better serving the "14th Five-Year Plan" development goals and the construction of a financial power [1][7]. Group 1: Market Developments - The first batch of new registered companies in the Sci-Tech Innovation Board's growth layer was listed on October 28, marking a significant advancement in the board's reform and development [1]. - Three unprofitable companies, He Yuan Biological-U (688765.SH), Xi'an Yicai-U (688783.SH), and Bibete-U (688759.SH), collectively went public [1]. - As of now, the number of companies in the Sci-Tech Innovation Board's growth layer has reached 35, with a total of 592 listed companies on the board [6]. Group 2: Regulatory and Institutional Support - The CSRC has successfully implemented the "1+6" reform policy since June, which includes the introduction of professional institutional investors and pre-review systems [5]. - The Shanghai Municipal Government is actively collaborating with the CSRC to enhance the operational stability and functionality of the Sci-Tech Innovation Board [5]. - The Shanghai Stock Exchange (SSE) has completed preparations for rules, technology, and market readiness within four months following the reform policy's release [6]. Group 3: Future Plans and Strategic Focus - The CSRC plans to research and formulate strategic tasks and major initiatives for the capital market during the "14th Five-Year Plan" period, focusing on risk prevention, strong regulation, and promoting high-quality development [7]. - The SSE will focus on four key areas: maintaining the "hard technology" positioning, promoting development through reform, enhancing regulatory effectiveness, and prioritizing investor protection [8].

Core Viewpoint - The article discusses the successful listing of Wuhan Heyuan Bio on the Sci-Tech Innovation Board, marking a significant milestone in the revival of the board's fifth set of listing standards for unprofitable companies, particularly in the biotech sector [3][6]. Group 1: Industry Overview - The Sci-Tech Innovation Board has prioritized the biopharmaceutical industry since its inception in 2019, with a total market capitalization of 1.13 trillion yuan for 110 listed biopharmaceutical companies as of December 2024 [5]. - The biopharmaceutical sector faces challenges due to long R&D cycles, high investment costs, and low success rates, leading to a significant drop in IPOs from 36 in 2021 to just 1 in 2024 on the Sci-Tech Innovation Board [6]. - The reintroduction of the fifth set of standards has opened new capital windows for unprofitable hard-tech companies, with Heyuan Bio being the first to successfully list under these new guidelines [6][13]. Group 2: Company Highlights - Heyuan Bio specializes in plant-derived recombinant protein expression technology and has developed a product, Aofumin®, which is the first human serum albumin injection based on recombinant protein technology in China [11][12]. - The company has received significant strategic investments from various institutions, including Yifeng Capital, which has supported Heyuan Bio through multiple funding rounds, demonstrating a commitment to long-term investment [12][13]. - The successful listing of Heyuan Bio is seen as a validation of Yifeng Capital's strategic foresight and investment approach in the biopharmaceutical sector [20]. Group 3: Investment Insights - Yifeng Capital has been a key player in the recent successes of Heyuan Bio, North Chip Life, and Tainuo Maibo, showcasing its ability to identify and support promising biotech companies [7][20]. - The firm has built a robust investment strategy focused on long-term value creation, aligning with the principles of nurturing innovation and supporting the commercialization of scientific advancements [20]. - Yifeng Capital's CEO emphasizes the importance of time in developing innovative companies, positioning the firm as a "runner" alongside scientists rather than a short-term profit seeker [20].

Core Viewpoint - He Yuan Bio's innovative drug "Aofumin" (recombinant human albumin injection derived from rice) has been approved for market entry, aiming to disrupt the traditional human blood albumin market by eliminating reliance on plasma-derived materials [1][14][27] Company Overview - He Yuan Bio was established in 2006 and has developed a proprietary rice endosperm cell bioreactor expression system over 19 years, leading to multiple drug products and research reagents [6][27] - The company is currently unprofitable but has achieved commercialization of several products, contributing millions in annual revenue [6][7] Product Launch and Market Performance - "Aofumin" was listed on the Sci-Tech Innovation Board at an initial price of 29.06 CNY per share, opening at 88 CNY, reflecting a significant increase of 202.82% [1][2] - As of 9:35 AM, the stock price was 78.2 CNY, with a market capitalization of 314.64 billion CNY [1][2] Revenue Structure - The revenue from drug excipients and research reagents has shown significant growth, with drug excipients contributing 565.74 million CNY in the first half of 2025, representing a 47.25% increase [7] - The total revenue for the first half of 2025 reached 1.197 billion CNY, with research reagents contributing 631.59 million CNY, a 52.75% increase [7] Technological Advancements - He Yuan Bio's third-generation technology platform has overcome key technical challenges in producing recombinant human albumin, allowing for high yield, simple processes, and low-cost production [7][9] - The company has established eight product pipelines, with "Aofumin" being the first to receive approval [11][13] Market Potential and Competitive Landscape - The global recombinant human albumin market is expected to grow, with "Aofumin" positioned as a potential substitute for traditional human blood albumin products [15][19] - The Chinese human blood albumin market is projected to grow from 25.8 billion CNY in 2020 to 57 billion CNY by 2030 [19] Regulatory and Clinical Development - "Aofumin" has been prioritized for review due to its classification as a critical drug for treating severe conditions, receiving approval in July 2025 [14][18] - The company plans to expand the indications for "Aofumin" through global multi-center clinical trials, aiming for approvals in the US and Europe [18][26] Pricing and Commercialization Strategy - The initial retail price for "Aofumin" is reported to be 890 CNY for a 10g specification, with no immediate price advantage over plasma-derived products [23][24] - He Yuan Bio has established a sales network across over 30 provinces in China, partnering with major distributors to enhance market penetration [22][25] Future Outlook - The successful launch of "Aofumin" marks a significant step in the commercialization of plant-derived recombinant human albumin, with potential to reshape the blood product market [27][29] - Continued investment in research and development is expected to enhance production capabilities and expand the product pipeline [27][29]